Big pharma generally is thought to be a safe haven for exchange traded fund (ETF) investors in times of uncertainty because people always will need prescriptions. However, some experts say the stereotype might not hold true anymore because of FDA setbacks and drug withdrawals, reports Trang Ho for Investor’s Business Daily. Some experts say that international investing is replacing big pharma as the new "safe haven." While U.S. agencies may play a role in health care, perhaps looking at it from a global perspective might add value, especially if they satisfy any of the aging baby boomers’ needs.
To take advantage of global health care companies that profit from the U.S. and abroad, consider iShares S&P Global Health Care Sector (IXJ). IXJ holds 79 stocks and is heavily weighted in the U.S at 65%. It also holds 12% in Switzerland, 11% in the U.K., 5% in Japan and 4% in France. It’s up 2.9% year-to-date.
The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.